PharmaEssentia appoints Eric Vogel as U.S. Head of Commercialization ahead of potential launch of BESREMi(R) in essential thrombocythemia.

{
  "signal_id": "c1ea5501-98b9-409c-8ee5-d0a156a655fd",
  "signal_type": "news",
  "signal_subtype": "leaves",
  "detected_at": "2026-05-27T16:34:00+00:00",
  "company": {
    "name": "Incyte",
    "domain": "incyte.com"
  },
  "data": {
    "url": "https://www.businesswire.com/news/home/20260527508196/en/PharmaEssentia-Appoints-Eric-Vogel-as-U.S.-Head-of-Commercialization-Ahead-of-Potential-Launch-of-BESREMi-in-Essential-Thrombocythemia",
    "title": "PharmaEssentia appoints Eric Vogel as U.S. Head of Commercialization ahead of potential launch of BESREMi(R) in essential thrombocythemia.",
    "ticker": "NASDAQ:INCY",
    "contact": "Vogel",
    "excerpt": "PharmaEssentia appoints Eric Vogel as U.S. Head of Commercialization ahead of potential launch of BESREMi(R) in essential thrombocythemia.\n\nFormer Incyte commercial executive brings deep hematology and MPN market experience\n\nBURLINGTON, Mass.-(BUSINESS WIRE)-PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical company headquartered in Taiwan, announced that Eric Vogel has joined the company as U.S. Head of Commercialization. A seasoned commercial leader with more than 20 years of experience in oncology and hematology, Vogel will support Samuel Lin, Head of Global Operations, in driving the commercial growth of BESREMi(R)(ropeginterferon alfa-2b-njft) for approved uses across global markets.\n\nVogel joins PharmaEssentia from Incyte Corporation, where he most recently served as Group Vice President of Sales and Marketing, overseeing a broad oncology and hematology portfolio, including commercial activities within the myeloproliferative neoplasm (MPN) market. During his tenure at Incyte, he built and led a high-performing sales organization and played a key role in driving significant commercial growth and consistently exceeding market expectations.\n\n\"We are very pleased to welcome Eric to PharmaEssentia,\" said Ko-Chung Lin, Ph.D., Founder and Chief Executive Officer of PharmaEssentia. \"His deep expertise in hematology and the MPN market, combined with his strong...",
    "summary": "Vogel leaves Incyte Corporation as Group Vice President of Sales and Marketing.",
    "planning": false,
    "image_url": "https://mms.businesswire.com/media/20260527508196/en/2816249/22/260408-PEC-logo-V500-5.jpg",
    "job_title": "Group Vice President of Sales and Marketing",
    "confidence": 0.7404,
    "product_tags": [
      "marketing"
    ],
    "published_at": "2026-05-27T16:34:00Z",
    "job_title_tags": [
      "marketing",
      "directors",
      "sales"
    ],
    "article_sentence": "Vogel joins PharmaEssentia from Incyte Corporation, where he most recently served as Group Vice President of Sales and Marketing, overseeing a broad oncology and hematology portfolio, including commercial activities within the myeloproliferative neoplasm (MPN) market."
  }
}

curl https://signals.autobound.ai/v1/signals/c1ea5501-98b9-409c-8ee5-d0a156a655fd \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"incyte.com","limit":20}'